Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 1255 results for "ranbaxy"

Ranbaxy says U.S. authorities seek information on pricing data

Ranbaxy Says US Seeking Information On Pricing Data

Generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement ... Businessworld India, 2 days ago
Ranbaxy told to give pricing data info in US Times of India, 3 days ago

122 images for ranbaxy

Business Today India, 1 day ago
Financial Express, 1 day ago
Sify, 1 day ago
NDTV, 1 day ago, 1 day ago
Reuters India, 1 day ago, 1 day ago
Reuters, 3 days ago, 3 days ago
MSN India, 1 week ago

US Department of Justice asks Ranbaxy to submit pricing data

, one of the leading pharma players, said the company has received a civil investigative demand (CID) from the United States Department of Justice. The civil investigative demand is related to the manner in which the company reports pricing data for certain ...
 Myiris3 days ago Ranbaxy receives CID from US Department of Justice  MyIris3 days ago Ranbaxy receives CID from US Justice Department  Money Control3 days ago Ranbaxy gets civil investigative demand from US on pricing issues  Livemint.com3 days ago

Bull's Eye: Buy Siemens, Crompton, NBCC, Ranbaxy, Biocon

Meghana V Malkan, advises buying Crompton Greaves for a target price of Rs 221 and Century Textiles for a target price of Rs 595.
 Money Control3 days ago Super Six buy or sell calls for September 18  Money Control3 days ago Buy Ranbaxy; sell Rel Cap, CESC, Adani Ent: Meghana Malkan  Money Control4 days ago Bull's Eye: Buy Lupin, HDFC; short HDIL, Reliance Capital  Money Control4 days ago
Business Standard

Gilead inks licensing pacts for Hep C drug with Ranbaxy, Cipla, Mylan, four Indian firms

Seven India-based firms - Ranbaxy, Cipla, Mylan, Cadila, Hetero, Sequent and Strides Arcolab - will produce hepatitis C medicines for distribution in 91 developing countries BS B2B Bureau | New Delhi September 17, 2014 Last Updated at 13:18 IST In what could ...
 Business Standard4 days ago Angel Broking remains neutral on Ranbaxy Labs  MyIris5 days ago Hepatitis C licence and drug firms  Hindu Business Line5 days ago Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others  Yahoo! Finance6 days ago
Money Control

Here are top 10 stocks to watch on Sep 18

Here are top 10 stocks to watch on Sep 18 - GMR Infra, Reliance Industries, Sun Pharma, Ranbaxy, Texrail, ITC, MCX, Yes Bank, Rel Comm and Aegis Logistics.
 Money Control3 days ago Stocks in news: Sun Pharma, Ranbaxy, YES Bank, Apollo Tyres  Money Control3 days ago Here are top 10 stocks to keep an eye on August 25  Money Control3 weeks ago Top10 stocks to watch on July 14  Money Control2 months ago

US Justice Dept Asks Ranbaxy for Drug Pricing Information

India, China Sign Three Pacts Within Hours of Xi's Arrival Breaking from protocol, Prime Minister Narendra Modi today unrolled a grand welcome for Chinese... Nawaz Sharif, Top Officials Booked for Murder of Protestors A murder case has been registered against ...
 Outlook3 days ago US Justice Dept demands drug pricing info from Ranbaxy  Rediff.com3 days ago

Price cuts announced by NPPA to hit Ranbaxy, Cipla the most

New Delhi|Mumbai: Ranbaxy Labs and Cipla are among the companies which would face the maximum brunt of the new price cuts announced by National Pharma Pricing Authority (NPPA) early this week. The drug pricing regulator capped prices of 43 ...
 Economic Times2 days ago UPDATE 2-India caps prices of 36 more drugs to improve access -govt official  Reuters UK1 day ago Delhi caps prices of 36 more medicine  The Gulf Today1 day ago Centre caps 36 drugs prices  Deccan Chronicle1 day ago

Pharma majors to be hit as drug regulator caps prices

In a move that might impact major drug makers such as Ranbaxy, Cipla, Cadila Health, and Lupin, the National Pharmaceutical Pricing Authority (NPPA) has capped the prices of 19 medicines and their 43 different drug packs, including anti-infectives, ...
 Business Standard India2 days ago Pharma firms to be hit as drug regulator caps prices  Rediff.com2 days ago

US demands pricing data from Ranbaxy

Drug-maker Ranbaxy Laboratories has been asked to furnish details on its products eligible for reimbursements from the US Government, the company informed the Bombay Stock Exchange on Wednesday. The company appears to have fallen foul of the US ...
 Hindu Business Line3 days ago Ranbaxy Laboratories : US DEMANDS PRICING DATA FROM RANBAXY  4 Traders2 days ago

Ranbaxy may lose exclusivity on Nexium generic

Ranbaxy was expected to launch its low-cost version in May, when the Nexium patent expired. Photo: Pradeep Gaur/Mint The Indian drug maker may lose the six-month market exclusivity for the Nexium copy in the US as there is pressure mounting on the ...
 Livemint.com3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy
Get updated on latest news & your favorite topics right in your inbox!
More     Less